Latest Insider Transactions at Avenue Therapeutics, Inc. (ATXI)
This section provides a real-time view of insider transactions for Avenue Therapeutics, Inc. (ATXI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AVENUE THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AVENUE THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2024
|
Jay D Kranzler Director |
SELL
Open market or private sale
|
Direct |
61
-9.84%
|
$122
$2.24 P/Share
|
|
Sep 30
2024
|
Jay D Kranzler Director |
BUY
Open market or private purchase
|
Direct |
497
+44.49%
|
$994
$2.5 P/Share
|
|
Sep 27
2024
|
Jay D Kranzler Director |
BUY
Open market or private purchase
|
Direct |
3
+2.38%
|
$6
$2.4 P/Share
|
|
Sep 23
2024
|
Alexandra Mac Lean Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+50.0%
|
-
|
|
Sep 23
2024
|
David Jin Interim PFO and COO |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+50.0%
|
-
|
|
Apr 16
2024
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
413,507
+10.44%
|
-
|
|
Jan 02
2024
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
2,101,496
+40.14%
|
-
|
|
Dec 11
2023
|
Robert L Davidow > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
353,000
-38.72%
|
$0
$0.14 P/Share
|
|
Dec 11
2023
|
Robert L Davidow > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
264,000
-27.94%
|
$0
$0.14 P/Share
|
|
Sep 08
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
418,410
+28.84%
|
$0
$0.72 P/Share
|
|
Sep 08
2023
|
Lindsay A Md Rosenwald Director |
BUY
Open market or private purchase
|
Direct |
348,675
+49.6%
|
$0
$0.72 P/Share
|
|
Mar 31
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
52,419
+7.87%
|
-
|
|
Jan 03
2023
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
231,316
+29.17%
|
-
|
|
Dec 31
2022
|
Fortress Biotech, Inc. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
90,909
+21.59%
|
-
|
|
Oct 11
2022
|
Inva Gen Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
388,888
-100.0%
|
$2,722,216
$7.71 P/Share
|
|
Dec 17
2021
|
Curtis Gale Oltmans Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,020
+50.0%
|
-
|
|
Dec 17
2021
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
69,020
+16.43%
|
-
|
|
Dec 17
2021
|
Jay D Kranzler Director |
BUY
Grant, award, or other acquisition
|
Direct |
69,020
+21.57%
|
-
|
|
Dec 17
2021
|
Joseph Walter Vazzano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,505
+37.75%
|
-
|
|
Dec 17
2021
|
Lu Lucy President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
411,616
+35.47%
|
-
|
|
Sep 15
2021
|
Joseph Walter Vazzano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,160
-9.89%
|
$7,160
$1.62 P/Share
|
|
May 06
2021
|
Neil Herskowitz Director |
BUY
Open market or private purchase
|
Direct |
2,500
+1.82%
|
$7,500
$3.99 P/Share
|